0 Proceedings of the ECOWAS 2nd Lassa Fever International Conference in Abidjan September 2025 Safety and tolerability of Favipiravir compared to ribavirin for the treatment of Lassa fever: A randomized controlled open-label phase II clinical trial [Conference Abstract] August 16, 2025 by Allan Mwesiga
0 Proceedings of the ECOWAS 2nd Lassa Fever International Conference in Abidjan September 2025 Assessment of treatment outcome and associated stigmatization and discrimination among Lassa fever patients treated at the Benue State Treatment Centre, Makurdi, Benue State, Nigeria [Conference Abstract] August 16, 2025 by Esther Butamanya
0 Proceedings of the ECOWAS 2nd Lassa Fever International Conference in Abidjan September 2025 Assessment of vaccine acceptance and perceptions of Lassa fever among acutely ill patients in Edo State, Nigeria: Findings from a cross-sectional study [Conference Abstract] August 16, 2025 by Esther Butamanya
0 Proceedings of the ECOWAS 2nd Lassa Fever International Conference in Abidjan September 2025 Forecasting Lassa fever risk to enable smarter, targeted interventions [Conference Abstract] August 16, 2025 by Irene Among
0 Proceedings of the ECOWAS 2nd Lassa Fever International Conference in Abidjan September 2025 Clinical presentation and predictors of severity in Lassa fever patients at a tertiary hospital in Abakaliki, Nigeria, 2018-2024 [Conference Abstract] August 15, 2025 by Irene Among
0 Proceedings of the ECOWAS 2nd Lassa Fever International Conference in Abidjan September 2025 Early action review of Lassa fever outbreaks in Nigeria: Utilizing the 7-1-7 framework as a performance improvement metric [Conference Abstract] August 15, 2025 by Irene Among
